|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLCO4C1 |
Gene summary for SLCO4C1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLCO4C1 | Gene ID | 353189 |
| Gene name | solute carrier organic anion transporter family member 4C1 | |
| Gene Alias | OATP-H | |
| Cytomap | 5q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q6ZQN7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 353189 | SLCO4C1 | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 5.62e-03 | 3.92e-01 | -0.1408 |
| 353189 | SLCO4C1 | RNA-P10T2-P10T2-4 | Human | Lung | AAH | 2.30e-02 | 2.70e-01 | -0.138 |
| 353189 | SLCO4C1 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 5.77e-24 | 1.08e+00 | -0.2116 |
| 353189 | SLCO4C1 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 1.59e-06 | 8.46e-01 | -0.1941 |
| 353189 | SLCO4C1 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 8.01e-07 | 1.01e+00 | -0.2107 |
| 353189 | SLCO4C1 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.60e-21 | 1.09e+00 | -0.2119 |
| 353189 | SLCO4C1 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.56e-02 | -1.90e-02 | -0.0132 |
| 353189 | SLCO4C1 | RNA-P8T2-P8T2-3 | Human | Lung | AIS | 1.80e-02 | 6.05e-01 | -0.1284 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLCO4C1 | SNV | Missense_Mutation | c.2132T>C | p.Val711Ala | p.V711A | Q6ZQN7 | protein_coding | tolerated(0.09) | benign(0.007) | TCGA-A2-A0T0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
| SLCO4C1 | SNV | Missense_Mutation | c.1804A>G | p.Ile602Val | p.I602V | Q6ZQN7 | protein_coding | tolerated(0.41) | benign(0.085) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| SLCO4C1 | SNV | Missense_Mutation | c.1690N>C | p.Glu564Gln | p.E564Q | Q6ZQN7 | protein_coding | tolerated(0.19) | benign(0.115) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SLCO4C1 | SNV | Missense_Mutation | c.2074N>A | p.Pro692Thr | p.P692T | Q6ZQN7 | protein_coding | deleterious(0.01) | possibly_damaging(0.54) | TCGA-BH-A1F0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SLCO4C1 | SNV | Missense_Mutation | c.328C>T | p.His110Tyr | p.H110Y | Q6ZQN7 | protein_coding | tolerated(0.12) | benign(0) | TCGA-D8-A13Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| SLCO4C1 | SNV | Missense_Mutation | c.325N>A | p.Leu109Ile | p.L109I | Q6ZQN7 | protein_coding | tolerated(0.07) | benign(0.019) | TCGA-D8-A1JD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| SLCO4C1 | SNV | Missense_Mutation | novel | c.603G>T | p.Leu201Phe | p.L201F | Q6ZQN7 | protein_coding | tolerated(0.27) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SLCO4C1 | SNV | Missense_Mutation | c.221N>C | p.Lys74Thr | p.K74T | Q6ZQN7 | protein_coding | tolerated(0.55) | benign(0.003) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| SLCO4C1 | SNV | Missense_Mutation | c.129T>G | p.Asn43Lys | p.N43K | Q6ZQN7 | protein_coding | tolerated(0.67) | benign(0.007) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
| SLCO4C1 | SNV | Missense_Mutation | c.556G>A | p.Ala186Thr | p.A186T | Q6ZQN7 | protein_coding | deleterious(0) | benign(0.141) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 353189 | SLCO4C1 | TRANSPORTER, DRUGGABLE GENOME | 178101436 | |||
| 353189 | SLCO4C1 | TRANSPORTER, DRUGGABLE GENOME | Digoxin | DIGOXIN |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |